64
Research Trials
29
Peer-reviewed publications
17
Clinical Conditions

Updated interim data from 54 COPD patients and 135,000 monitored hours, showing cough rates rise in the days before exacerbations and correlate only weakly with CAT scores.

A month of continuous monitoring in stable chronic cough shows that multi-day averaging makes cough frequency a more reliable trial endpoint, allowing smaller studies, and reveals a short-lived Hawthorne effect.

Mixed-methods study in Kampala assessing 48-hour cough frequency monitoring with the Hyfe Research app for TB screening and triage, alongside staff-reported implementation barriers.
27 February 2024 · Lung

Purpose: Codeine is a narcotic antitussive often considered for managing patients with refractory or unexplained chronic cough. This study aimed to evaluate the proportion and characteristics of patients who responded to codeine treatment in real-world practice.
Methods: Data from the Korean Chronic Cough Registry, a multicenter prospective cohort study, were analyzed. Physicians assessed the response to codeine based on the timing and degree of improvement after treatment initiation. Follow-up assessments included the Leicester Cough Questionnaire and cough severity visual analog scale at six months. In a subset of subjects, objective cough frequency was evaluated following the initiation of codeine treatment.
Results: Of 305 patients, 124 (40.7%) responded to treatments based on anatomic diagnostic protocols, while 181 (59.3%) remained unexplained or refractory to etiological treatments. Fifty-one subjects (16.7%) were classified as codeine treatment responders (those showing a rapid and clear response), 57 (18.7%) as partial responders, and 62 (20.3%) as non-responders. Codeine responders showed rapid improvement in objective cough frequency and severity scores within a week of the treatment. At 6 months, responders showed significantly improved scores in cough scores, compared to non-responders. Several baseline parameters were associated with a more favorable treatment response, including older age, non-productive cough, and the absence of heartburn.
Conclusions: Approximately 60% of chronic cough patients in specialist clinics may require antitussive drugs. While codeine benefits some, only a limited proportion (about 20%) of patients may experience rapid and significant improvement. This underscores the urgent need for new antitussive drugs to address these unmet clinical needs.
Bring objective cough data to your study. Schedule a meeting →